Exelixis Looks To Early-Stage Option Rights As Low-Risk Pipeline Expansion Play
The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.
You may also be interested in...
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
With help from Biomedtracker, Scrip takes a look at six drug candidates expecting pivotal data by the end of the year. The assets span a range of therapeutic areas, from ophthalmology to neurology, and are poised to become market firsts, rivals to dominant products or win important label expansions.
AstraZeneca and partner Daiichi Sankyo obtain the first approval for targeted therapy in HER2-low metastatic breast cancer for Enhertu, about four months ahead of the FDA action date.